Incyte's Revenue in the fiscal year 2025 $ 5,141.24 millions
Incyte's Revenue in the fiscal year 2024 $ 4,241.22 millions
Incyte's Revenue in the fiscal year 2023 $ 3,695.65 millions
Incyte's Revenue in the fiscal year 2022 $ 3,394.64 millions
Incyte's Revenue in the fiscal year 2021 $ 2,986.27 millions
INCY Revenue third quarter 2026 Y/Y Growth Comment
Incyte Corporation reported Revenue increase of 14% year on year in the third quarter 2026, to $ 1,557.20 millions, this is lower than Incyte Corporation's recent average Revenue improvement of 39.38%.
Looking into third quarter 2026 results within Medical Laboratories industry 13 other companies have achieved higher Revenue growth. While Incyte Corporation' s Revenue growth of 14% ranks overall at the positon no. 1013 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Incyte's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
408.95 %
16.7 %
-66.15 %
(Dec 31 2010)
INCY's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Incyte Corporation disclosed decline in Revenue from the second quarter by -6.98% to $ 1,557.20 millions, from $ 1,674.04 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.
Within Medical Laboratories industry 29 other companies have achieved higher Revenue quarter on quarter growth. While Incyte's Revenue growth quarter on quarter, overall rank is 3108.
In the III. Quarter 2026 Incyte Corporation disclosed decline in Revenue from the second quarter by -6.98% to $ 1,557.20 millions, from $ 1,674.04 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.
Within Medical Laboratories industry 29 other companies have achieved higher Revenue quarter on quarter growth. While Incyte's Revenue growth quarter on quarter, overall rank is 3108.
With the quarterly Revenue reported in the Sep 30 2026 period, Incyte's cumulative twelve months Revenue were $ 6,011 millions, company would post below average annual Revenue growth of 3.29% year on year, if the fiscal year would end at Sep 30 2026. A slow-down in the Incyte's Revenue growth from the 1674.04% growth in Jun 30 2026.
In the Healthcare sector 191 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 845 to 998.
With the quarterly Revenue reported in the Sep 30 2026 period, Incyte's cumulative twelve months Revenue were $ 6,011 millions, company would post below average annual Revenue growth of -46.54% year on year, if the fiscal year would end at Sep 30 2026. A slow-down in the Incyte's Revenue growth from the 1674.04% growth in Jun 30 2026.
In the Healthcare sector 191 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 845 to 998.
About Incyte Revenue Growth Rates (INCY), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
24.31%